Investigational drug · Phase 3
HRS-1780
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Kidney Disease, Uncontrolled or Resistant Hypertension, Primary Aldosteronism.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "HRS-1780"
First trial start
2026
Mar 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-1780", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Kidney Disease
- Uncontrolled or Resistant Hypertension
- Primary Aldosteronism
Approved drugs for the same conditions: High blood pressure (hypertension) · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-1780" as an intervention, largest first.
- A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney DiseasePivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07419828 · 5,386 participants (planned) · Start Mar 13, 2026 · Primary completion Apr 2030
Drug: HRS-1780 tablets; Placebo · For: Chronic Kidney Disease
Sites: Nanjing, China
- A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.Pivotal-lookingRecruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07708441 · 914 participants (planned) · Start Sep 29, 2026 · Primary completion Apr 2029
Drug: HRS-1780 tablet; HRS-1780 tablet and 2 more · For: Uncontrolled or Resistant Hypertension
Sites: Chongqing, China; Shanghai, China
- Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney DiseasePivotal-lookingCompleted
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06221059 · 181 participants · Start Mar 2, 2024 · Primary completion Mar 5, 2025
Drug: HRS-1780 tablet;Henagliflozin Proline tablet;HRS-1780 tablet placebo ;Henagliflozin Proline tablet placebo · For: Chronic Kidney Disease
Sites: Nanjing, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT05638126 · 96 participants · Start Feb 2, 2023 · Primary completion Dec 2023
Drug: HRS-1780 table or placebo; HRS-1780 table or placebo and 1 more · For: Chronic Kidney Disease
Sites: Chengdu, China
- A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary AldosteronismActive, not recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07470983 · 61 participants · Start Apr 23, 2026 · Primary completion Nov 2026
Drug: HRS-1780 Tablets; Placebo · For: Primary Aldosteronism
Sites: Chongqing, China; Zhengzhou, China
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06344936 · 28 participants (planned) · Start Apr 2024 · Primary completion Jul 2024
Drug: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules · For: Chronic Kidney Disease(CKD)
Sites: Beijing, China
- Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal FunctionStatus unknown
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06039254 · 27 participants (planned) · Start Sep 2023 · Primary completion Nov 30, 2023
Drug: HRS-1780 · For: Chronic Kidney Disease
Shandong Suncadia Medicine Co., Ltd.Industry
NCT06495931 · 24 participants · Start Jul 15, 2024 · Primary completion Aug 13, 2024
Drug: HRS-1780 tablets; HR20033 tablets and 1 more · For: Type 2 Diabetes Mellitus
Sites: Beijing, China
- A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male SubjectsNot yet recruiting
Shandong Suncadia Medicine Co., Ltd.Industry
NCT07557407 · 6 participants (planned) · Start May 2026 · Primary completion Jun 2026
Drug: [14C]HRS-1780 · For: Chronic Kidney Diseases
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
- Erratum: Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum].
· Drug Des Devel Ther 2025
- Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study.
Fei Y, Xie Z, Luo Y, et al. · Drug Des Devel Ther 2025
- A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid receptor antagonist, in healthy men.
Shen Q, Li L, Qian W, et al. · Expert Opin Investig Drugs 2024
Also in development for Chronic Kidney Disease
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ElecoglipronPhase 39 trials
AstraZeneca · Type 2 Diabetes Mellitus, Obesity, Overweight
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- lorundrostatPhase 35 trials
Mineralys Therapeutics Inc. · Hypertension, Obstructive Sleep Apnea, Chronic Kidney Disease
- VicadrostatBI 690517Phase 35 trials
Boehringer Ingelheim · Heart Failure, Diabetes Mellitus, Type 2, Hypertension
- ABP-671Phase 32 trials
Atom Therapeutics Co., Ltd · Chronic Kidney Disease, Gout
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.